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Introduction {#sec1}
============

Complement destroys invading microorganisms and initiates defense mechanisms including chemotaxis, phagocytosis, cell adhesion, B cell differentiation, and maintenance of immune tolerance ([@bib2], [@bib26]). It also facilitates tissue remodeling, homeostasis, and resolution of inflammation via apoptosis and clearance of cellular debris ([@bib1], [@bib33]). Defects in complement are associated with immunodeficiencies, autoimmune diseases, tissue damage, anaphylaxis, transplant rejection, and necrosis. Complement via the lectin pathway is initiated when mannan-binding lectin (MBL), serum ficolins, collectin-KL, and/or collectin-K1 bind to pathogens and activate MBL-associated serine proteases (MASP-1 and MASP-2 and MASP-3) ([Figure 1](#fig1){ref-type="fig"}). The importance of the lectin pathway is highlighted by common immunodeficiencies associated with mutations to MBL ([@bib37]) and MASP-2 ([@bib31]). Inappropriate lectin pathway activation causes tissue damage following transient ischemia ([@bib29]), so modulators of the lectin pathway are likely to have important therapeutic benefits.

MBLs are large oligomers (150--300 kDa), predominantly dimers to tetramers of a homotrimeric subunit ([@bib40]). In each homotrimer, pathogen recognition is mediated through the coordinated binding of three globular carbohydrate recognition domains (CRDs) connected to a rod-like collagenous stem ([Figure 1](#fig1){ref-type="fig"}). MASPs are homodimers that circulate as zymogens bound to the collagenous domains of MBL ([@bib41]). Each MASP comprises two N-terminal CUB (C1r/C1s, Uegf, and bone morphogenetic protein-1) domains separated by an epidermal growth factor (EGF)-like domain followed by two short complement regulator (SCR) domains and a C-terminal serine protease (SP) domain ([Figure 1](#fig1){ref-type="fig"}). MASP-1 and MASP-3 are alternatively spliced products from the same gene. Activation occurs following cleavage at a single site between the SCR2 and SP domains when MBLs bind to a pathogen surface. MASP-1 cleaves MASP-2, which subsequently cleaves the downstream complement components C4 and C4-bound C2 to form the C3 convertase ([@bib43]). MASP-1 and/or MASP-3 facilitate activation of the alternative pathway through activation of factors D and B ([@bib16], [@bib32]). It is often assumed that the MBLs adopt bouquet-like structures similar to complement C1q. Instead, our recent atomistic scattering modeling showed that they have near-planar, fan-shaped structures in solution ([Figure 1](#fig1){ref-type="fig"}), which raises new questions on how the complexes activate complement ([@bib20]). In two different theories following attachment of the MBL-MASP complex to a pathogenic surface, either (1) each monomer within the MASP dimer is able to bend significantly to enable one SP domain to activate its partner, as occurs for the MASP homologs, C1r and C1s within the C1 complex, or (2) a given MASP-MBL complex activates neighboring MASP molecules on adjacent MBL-MASP complexes ([@bib6], [@bib44]). A recent analysis by small- angle X-ray scattering (SAXS) and electron microscopy (EM) favored the inter-complex model, concluding that MASP-1 was only modestly flexible and the protease domains were too far apart to enable intra-complex activation ([@bib19]).

Here, we investigate the dimer structures of MASP-1 and MASP-2 through the combination of SAXS, analytical ultracentrifugation (AUC), and a new atomistic modeling procedure ([@bib23], [@bib24]). While several crystal structures are known for the N-terminal MASP fragments ([@bib8], [@bib10], [@bib12], [@bib30], [@bib34]) and for the C-terminal MASP fragments ([@bib7], [@bib9], [@bib13], [@bib14], [@bib18]), these are incomplete. In particular, MASP-2 CUB1-EGF-CUB2 (subsequently called MASP-2 3D) was crystallized in the presence of citrate that chelates Ca^2+^, and although Ca^2+^ was bound to the EGF-like domain, the CUB1 and CUB2 domains lacked Ca^2+^ and became partially disordered as a result ([@bib8]). Here, to complete our knowledge of the MASP structures, we first applied X-ray crystallography to the N-terminal fragments to identify the importance of bound Ca^2+^. Next, by applying our strategy to the zymogen and activated forms of MASP, we assessed whether the MASP dimer is sufficiently flexible to allow auto-activation or inter-molecular activation.

There are four potential binding sites for MBL stems on each MASP homodimer---one on each of the four CUB domains ([@bib41]; [Figure 1](#fig1){ref-type="fig"}). The crystal structures of collagen-like peptides bound to CUB1 and CUB2 mean we now know the MBL-MASP contacts at atomic resolution ([@bib10], [@bib38]). These structures reveal key contacts between an essential Lys46 residue in the collagen-like region of MBL and three Ca^2+^-binding residues in CUB2. The Ca^2+^-binding site is conserved in CUB1, which binds to a separate collagen stem. By comparing the MASP solution structures with models for MBL, we evaluated the MASP-MBL complexes that trigger complement activation. In particular, our new MASP structures clarify the extent to which the MASPs undergo significant conformational changes during activation after pathogen binding by MBL.

Results {#sec2}
=======

Purification and Crystal Structure Determination of MASPs {#sec2.1}
---------------------------------------------------------

Following the crystallography and scattering strategy used for rat MBL ([@bib20]), we expressed full-length rat MASP-1 and MASP-2 zymogens and both their 3D fragments for structural analysis ([Figure 1](#fig1){ref-type="fig"}). Repeated attempts to obtain diffracting crystals of full-length MASP-1 and MASP-2 were unsuccessful, probably due to inter-domain flexibility. An alternative strategy involving crystallography of MASP fragments was followed. Because there was no structure of rat MASP-1 3D, and the existing structure of rat MASP-2 3D lacked two of the three Ca^2+^, including those Ca^2+^ that form part of the binding site for MBL, both rat MASP-1 3D and MASP-2 3D were crystallized in the presence of 2 mM calcium and diffraction data were collected. This resulted in one MASP-1 structure at 3.7 Å resolution and three independent MASP-2 structures at 2.6--2.7 Å resolution ([Table 1](#tbl1){ref-type="table"}).

The four electron density maps were of high quality ([Figure S1](#mmc1){ref-type="supplementary-material"}). For MASP-1 3D, 276 of its 281 residues could be built into the electron density map. The resulting structure was similar to the corresponding structure of human MASP-1 (PDB: [3DEM](pdb:3DEM){#intref0010}), with a root-mean-square deviation (RMSD) of 0.961 Å over 267 residues ([@bib35]). For MASP-2 3D, 279 of 280 residues were visible. Interestingly, the three structures overlaid closely, with RMSDs of 0.682, 0.871, and 0.992 Å over 276 Cα atoms. The only notable differences were in the N-terminal seven residues and in a loop within the EGF-like domain (Thr125--Ser130), probably reflecting flexibility. All three MASP-2 3D structures were similar to the previous structure of rat MASP-2 3D (PDB: [1NT0](pdb:1NT0){#intref0015}) with RMSDs of 1.20, 1.35, and 1.57 Å over 257 Cα atoms ([@bib8]). A major difference, however, was that the structures now contained three bound Ca^2+^ compared with the single Ca^2+^ in the EGF-like domain of the earlier MASP-2 3D structure. Each CUB domain bound one Ca^2+^, where the Ca^2+^-binding residues and binding loops were well defined. These Ca^2+^ sites are functionally important because they orientate and form the binding site for MBL, ficolins, CL-KL, and CL-K1 ([@bib10]). All four crystal structures revealed a dimer of MASP-1 3D or MASP-2 3D, formed by antiparallel neighboring contacts between pairs of CUB1-EGF domains about the crystallographic symmetry axis ([Figures 2](#fig2){ref-type="fig"}A and 2B). The same dimer was seen in earlier crystal structures of MASPs (PDB: [1NT0](pdb:1NT0){#intref0020} and [3DEM](pdb:3DEM){#intref0025}), further supporting earlier conclusions that this is physiologically relevant ([@bib8], [@bib11], [@bib30], [@bib35]). The total buried surface area for MASP-1 at the dimer interface was 880 Å^2^ per molecule (1,760 Å^2^ in total), whereas the three crystal structures for MASP-2 gave 1,200, 1,090, and 950 Å^2^ per molecule. These values were in excess of 800 Å^2^, consistent with stable dimer formation ([@bib28]).

Bioavailable calcium is typically present in plasma at around 2.5 mM ([@bib15]). All four new crystal structures revealed well-ordered, similar calcium-binding sites in each of the CUB1 and CUB2 domains ([Figures 2](#fig2){ref-type="fig"}A and 2B). These were previously seen for human MASP-1 3D, but not for rat MASP-2 3D ([Figures 2](#fig2){ref-type="fig"}C and 2D). In the MASP-1 CUB1 domain, Ca^2+^ formed contacts with six oxygen atoms in the side chains of Glu49, Asp57, Asp102, Ser104, and Asn105 (distances between 2.3 and 2.4 Å). In the MASP-2 CUB1 domain, Ca^2+^ formed contacts with six oxygen atoms in the side chains of Glu48, Asp56, Asp101, and Asn104 and the main chain oxygen of Ser103 (distances between 2.3 and 2.7 Å; [Figure S1](#mmc1){ref-type="supplementary-material"}A). In the MASP-1 CUB2 domain, Ca^2+^ now formed contacts with five oxygen atoms in the structurally equivalent side chains of Glu216, Asp226, Asp263, and Ser265. In the MASP-2 CUB2 domain, Ca^2+^ formed contacts with five oxygen atoms at the side chains of Glu215, Asp225, Asp262, and Ser264 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This second site differed from that in CUB1 only by the omission of the side chain with the structurally equivalent Asn105/Asn104 oxygen atom in CUB2. Nonetheless, this Ca^2+^ site was similar to that reported in the CUB2 domain of MASP-1 alone ([@bib10]). Comparison of the same CUB1/CUB2 region in the earlier crystal structure of rat MASP-2 showed disorganized binding loops in the absence of calcium ([Figure 2](#fig2){ref-type="fig"}D), suggesting that Ca^2+^ stabilizes the MBL-binding residues. The EGF domains of MASP-1 and MASP-2 also bound calcium ([Figures 2](#fig2){ref-type="fig"}C and 2D).

X-Ray Scattering of Rat MASPs {#sec2.2}
-----------------------------

X-ray scattering measures by diffraction the overall structure of biological molecules in randomized orientations in solution ([@bib23]). Here, solution scattering identified the domain structures of MASP-1 3D, MASP-2 3D, MASP-1 zymogen/activated, and MASP-2 zymogen/activated, with and without Ca^2+^, in order to verify the structures seen by crystallography. The scattering data *I*(*Q*) were collected at concentrations dilute enough to minimize concentration effects (0.25--1.36 mg/mL). The MASPs showed no radiation damage or X-ray induced aggregation in the time frame analyses. The time-averaged runs were thus used for data analyses. Guinier analyses of the *I*(*Q*) data in two separate *Q* ranges gave the radius of gyration *R*~*g*~ and the cross-sectional radius of gyration *R*~*xs*~ ([Figure 3](#fig3){ref-type="fig"}).

The *R*~*g*~ value monitors the overall degree of elongation of the MASP dimers. At the lowest *Q* values, the *R*~*g*~ values were measured within satisfactory *Q.R*~*g*~ limits in concentration series between 0.25 and 1.26 mg/mL for the six MASPs ([Figure 3](#fig3){ref-type="fig"}A). The mean of two to four *R*~*g*~ values were 3.83 ± 0.02 nm for MASP 3D and 7.73 ± 0.20 nm for full-length MASP ([Table 2](#tbl2){ref-type="table"}). The *R*~*g*~ values for the full-length MASPs were almost double those of the MASP 3Ds, this being as expected if the full-length MASPs have extended six-domain structures. No change with protein concentrations in either the *I*(*0*)*/c* or *R*~*g*~ values for each of the six MASPs was observed. This meant that no self-association or conformational change in MASP was detectable with change in protein concentration. No change between the pairs of *R*~*g*~ values for zymogen and activated MASP-1 and MASP-2 was seen ([Table 2](#tbl2){ref-type="table"}), indicating that their domain arrangements were unaffected by cleavage of the SCR2-SP linker.

The cross-sectional *R*~*xs*~ Guinier analyses monitored the shorter dimensions of the MASP dimers. The ln *I*(*Q*)*.Q* versus *Q*^*2*^ plots showed linear regions in the 3D and full-length proteins ([Figure 3](#fig3){ref-type="fig"}B), indicating that both proteins were elongated. The resulting *R*~*xs*~ values for MASP-1 3D and MASP-2 3D were similar at 1.94 ± 0.01 nm and 1.74 ± 0.02 nm, respectively ([Table 2](#tbl2){ref-type="table"}). For the full-length zymogen and activated MASP, the four *I*(*Q*)*.Q* versus *Q*^*2*^ plots showed inflexions before a linear *R*~*xs*~ region, indicating complex but similar domain arrangements in MASPs. The resulting *R*~*xs*~ values were indistinguishable for zymogen and activated MASP-1 (at 1.53--1.54 nm) and MASP-2 (both at 1.46 nm). This indicated no major conformational differences between the zymogen and activated forms, even with the addition or removal of Ca^2+^. The similar *R*~*xs*~ values for MASP-1 and MASP-2 indicated that both showed similar cross-sectional structures.

The distance distribution function *P*(*r*) represented all the distances between pairs of atoms within the macromolecule. This provided structural information in real space. The *P*(*r*) curve provided an alternative calculation of the Guinier *R*~*g*~ value and gave maximum lengths (*L*) following an assumption of the maximum dimension (*D*~*max*~). The *R*~*g*~ values from *P*(*r*) were similar to those from the Guinier analyses as expected ([Table 2](#tbl2){ref-type="table"}). The maximum length *L* of the MASPs was determined from the *r* value when *P*(*r*) = 0 at large *r* ([Figure 4](#fig4){ref-type="fig"}C). For both 3D MASPs, a single peak was observed in *P*(*r*) with the most common intra-particle distance at a maximum *M* of 3.9 nm and a length *L* of 13 nm. This *M* value corresponds well to the mean intra-domain distance within the four CUB domains. For zymogen and activated full-length MASP, two peaks *M1* and *M2* at 3.4 nm and 10.7 nm, respectively, were seen. *M1* was assigned to structures similar to those in MASP 3D. *M2* corresponded well to the distances between the two SP domains and the CUB domains in the center of the MASP dimer.

Analytical Ultracentrifugation of Rat MASPs {#sec2.3}
-------------------------------------------

AUC studies solution structures by monitoring their sedimentation under high centrifugal force ([@bib4]). This provided information on the structure and oligomerization of MASP. The latter was important because the MASPs were purified in low 20 mM NaCl salt, which may promote oligomer formation. Sedimentation velocity experiments were performed on the six MASPs at concentrations similar to those used for SAXS in physiological ionic strength conditions in the same buffers with Ca^2+^ or EDTA ([Figures 4](#fig4){ref-type="fig"}A and 4E). The velocity data were analyzed using absorbance optics to generate the size distribution analyses *c*(*s*). The analyses of up to 80 boundaries revealed excellent fits and satisfactory RMSDs. The mass determination from the single *c*(*s*) peak showed that all six samples were dimers with no detectable monomer or higher oligomer ([Figures 4](#fig4){ref-type="fig"}B--4D and 4F--4H). The molecular mass of MASP-1 3D was 74 ± 2 kDa, and that for MASP-2 3D was 65 ± 2 kDa, in good agreement with sequence-calculated masses of 75 kDa for MASP-1 3D and 74 kDa for MASP-2 3D. That for zymogen MASP-1 was 163 ± 6 kDa, activated MASP-1 was 158 ± 6 kDa, zymogen MASP-2 was 147 ± 6 kDa, and activated MASP-2 was 166 ± 1 kDa. These values agreed well with the sequence-predicted masses of 170 kDa and 163 kDa for full-length MASP-1 and MASP-2 dimers, respectively. The sedimentation coefficient *s*~*20,w*~ provided an independent measure of macromolecular elongation. The *s*~*20,w*~ values of MASP-1 3D and MASP-2 3D were 4.53 S and 4.09 S, respectively ([Table 2](#tbl2){ref-type="table"}). The *s*~*20,w*~ values of zymogen and activated MASP-1 were 5.90 S and 5.79 S, respectively, and those for zymogen and activated MASP-2 were 5.42 S and 5.62 S, respectively ([Table 2](#tbl2){ref-type="table"}). The *s*~*20,w*~ value for MASP-2 3D was similar to that of 4.55 ± 0.10 S reported previously ([@bib8]).

The availability of initial models or structures for MASP permitted comparison of the experimental *s*~*20,w*~ values with those predicted from these. The precision of the comparisons is ±0.21 S ([@bib24]). Interestingly, the prediction of 4.26 S from the MASP-1 3D crystal structure was similar to the observed value of 4.53 ± 0.08, while that of 4.18 S from the MASP-2 crystal structure was close to the observed value of 4.09 ± 0.07 S ([Table 2](#tbl2){ref-type="table"}). The solution structures of both proteins thus broadly resembled those seen by crystallography ([Figures 2](#fig2){ref-type="fig"}A and 2B). In distinction, for the zymogen and activated forms of MASP-1 and MASP-2, these comparisons showed deviations from the initial models. For the full-length MASPs, the initial predictions of 5.38 S, 5.50 S, 5.28 S, and 5.28 S ([Figures 4](#fig4){ref-type="fig"}C, 4D, 4G, and 4H) were lower than the observed values of 5.90 ± 0.15 S, 5.79 ± 0.13 S, 5.42 ± 0.15 S, and 5.62 ± 0.16 S, respectively ([Table 2](#tbl2){ref-type="table"}), indicating that the solution structures were more bent than the initial extended homology models. This evidence for more compact structures indicated flexibility in the MASP-1 and MASP-2 structures that had not been previously recognized.

Atomistic Scattering Modeling of Rat MASPs {#sec2.4}
------------------------------------------

As for rat MBL ([@bib20]), atomistic modeling for the six MASPs assessed whether the two linear MASP 3D crystal structures and four linear homology models for full-length MASP agreed with the experimental SAXS data. The predicted *R*~*g*~ values of 3.62 nm and 3.58 nm from the MASP-1 3D and MASP-2 3D crystal structures were less than but similar to the observed *R*~*g*~ values of 3.79 ± 0.01 nm and 3.87 ± 0.02 nm ([Table 2](#tbl2){ref-type="table"}; [Figures 5](#fig5){ref-type="fig"}A and 5D) to indicate that their solution structures broadly resembled their crystal structures ([Figures 2](#fig2){ref-type="fig"}A and 2B). In contrast, the linear homology models of zymogen and activated full-length MASP-1 gave predicted *R*~*g*~ values of 9.00 nm and 8.68 nm that were 10--13% greater than the observed *R*~*g*~ values of 7.93 ± 0.09 nm and 7.86 ± 0.12 nm ([Table 2](#tbl2){ref-type="table"}; [Figures 5](#fig5){ref-type="fig"}B and 5C). The predicted *R*~*g*~ values of 8.36 nm and 8.23 nm for the initial models of zymogen and activated full-length MASP-2 were likewise 9--10% greater than the observed *R*~*g*~ values of 7.58 ± 0.13 nm and 7.54 ± 0.04 nm ([Table 2](#tbl2){ref-type="table"}; [Figures 5](#fig5){ref-type="fig"}E and 5F). These *R*~*g*~ differences show that the full-length proteins in solution were more bent and compact in shape than the linear initial models, in agreement with the modeling of the *s*~*20,w*~ values.

To identify detailed 3D solution structures, atomistic modeling searches were performed ([@bib24]). The MASP 3D crystal structures were used to generate physically realistic structures. Regions of flexibility were assigned to the EGF-CUB2 linkers and C-terminal hexaHis tags ([Figure 1](#fig1){ref-type="fig"}). The CUB1-EGF dimer contacts did not allow flexibility at the CUB1-EGF linker. Using a Monte Carlo procedure, the EGF-CUB2 linker peptides were randomized to generate 1,982--4,517 trial MASP 3D structures for computing their SAXS curves. A large improvement in the goodness-of-fit *R* factor to 4.8%--7.4% was obtained, compared with 9.2%--11.2% for the two crystal structures ([Figures 5](#fig5){ref-type="fig"}A and 5D). This decrease showed that the use of flexible EGF-CUB2 linkers resulted in significantly improved curve fits ([Figures 6](#fig6){ref-type="fig"}A and 6D). When two N-glycan oligosaccharides in extended conformations were added to the structures, the agreement between the experimental and calculated *I*(*Q*) and *P*(*r*) curves improved to *R* factors of 4.1%--4.2% ([Figures 6](#fig6){ref-type="fig"}A and 6D). All ten best-fit structures retain this conformational feature, being bent inward toward the center of the MASP 3D dimer ([Figures 7](#fig7){ref-type="fig"}A and 7D). When the degree of bending was parameterized ([Figure S2](#mmc1){ref-type="supplementary-material"}A), the separation of 9.8--10.0 nm between the centers of the CUB2 domains in the two crystal structures was almost unchanged at 9.5 ± 0.5 nm in the ten best-fit models for MASP-1 3D and MASP-2 3D, while the angle between the two CUB2 domains was significantly decreased from 171° to as low as 142 ± 8° ([Table S1](#mmc1){ref-type="supplementary-material"}). As an independent check of the modeling, the predicted *s*~*20,w*~ values from the ten best-fit models for each of MASP-1 3D and MASP-2 3D gave mean values of 4.25 ± 0.07 S and 3.96 ± 0.03 S. These were similar to the experimental *s*~*20,w*~ values of 4.53 ± 0.08 S and 4.09 ± 0.07 S, as for the two crystal structures ([Figures 2](#fig2){ref-type="fig"}A and 2B). In conclusion, while our atomistic modeling revealed similar extended MASP 3D structures in solution and in the crystal, the final SAXS models indicated large differences in the two 3D structures in which the CUB2 domains were bent right back, as much as vertically upward from the plane of the CUB1-EGF domains ([Figures 6](#fig6){ref-type="fig"}A, 6D, [7](#fig7){ref-type="fig"}A, and 7D). Importantly for function, these differences suggest that the EGF-CUB2 junction is a flexible hinge with a 90° flex ([Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}).

Atomistic SAXS modeling was also performed for full-length MASPs using the linear homology models to generate physically realistic varied structures. Flexible regions were assigned at the EGF-CUB2, CUB2-SCR1, SCR1-SCR2, and SCR2-SP linkers and the N-terminal hexaHis tags. The MASP 3D crystal structure was used in this. By a Monte Carlo procedure, the five linker peptides were varied to generate 6,173--30,910 trial MASP structures. The resulting goodness-of-fit *R* factors versus *R*~*g*~ values ([Figures 5](#fig5){ref-type="fig"}B, 5C, 5E, and 5F) showed that the linear homology model *R* factor values of 7.7%--9.1% were reduced to 6.5%--7.1% for the best-fit models. In addition, the best-fit models showed better agreements between the experimental and modeled *R*~*g*~ values. Bends in the four inter-domain linkers thus resulted in improved curve fits ([Figures 6](#fig6){ref-type="fig"}B, 6C, 6E, and 6F). When three N-glycosylation oligosaccharides were added to the MASP structures ([Figure 1](#fig1){ref-type="fig"}), the *R* factors were improved further to 4.6%--5.2% ([Figures 6](#fig6){ref-type="fig"}B, 6C, 6E, and 6F). Increasing the number of trial models showed no further improvement in *R* factors. A control Search 2 started from the best-fit scattering models for MASP 3D and not their crystal structures and gave unchanged *R* factors of 4.2%--5.8% ([Figures 5](#fig5){ref-type="fig"}B, 5C, 5E, 5F, [6](#fig6){ref-type="fig"}B, 6C, 6E, and 6F). In summary, the ten best-fit scattering structures showed that the SP domains at the extremities of the dimer move toward each other to create bent structures ([Figures 7](#fig7){ref-type="fig"}B, 7C, 7E, and 7F).

The extent of bend in the final full-length MASP-1 and MASP-2 models was parameterized ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The initial separation of 27--29 nm (MASP-1) and 24--25 nm (MASP-2) between the SP domains in the starting models was reduced to 20--22 nm (MASP-1) and 16--20 nm (MASP-2) in the ten best-fit models ([Table S1](#mmc1){ref-type="supplementary-material"}). While the two zymogens may be more compact than the two activated MASPs, any difference was small. The *θ*3 angles between the two SP domains decreased from 166°--172° in the starting models to 100°--142° ([Table S1](#mmc1){ref-type="supplementary-material"}). As an independent check of the modeling, the predicted *s*~*20,w*~ values from the ten best-fit models for zymogen and activated MASP-1 gave mean values of 5.92 S and 5.92 S, and those for zymogen MASP-2 and activated MASP-2 were 5.69 S and 5.61 S. These agreed better with the experimental *s*~*20,w*~ value of 5.90 S, 5.79 S, 5.42 S, and 5.62 S in that order ([Table 2](#tbl2){ref-type="table"}) than the initial predictions (see above). In conclusion, we have demonstrated bent and flexible MASP-1 and MASP-2 structures in which the two SP domains are closer together.

Discussion {#sec3}
==========

Our crystal structures and X-ray scattering data for six rat MASPs revealed a novel understanding of their solution structures and in particular on their flexibility. We report new experimental structures for intact full-length MASP-1 and MASP-2 and the first identification of flexible junctions between the MASP domains. The SAXS data were supported by ultracentrifugation and atomistic scattering modeling, showing that the full-length MASP solution structures are significantly bent. The EGF-CUB2 junction appeared highly flexible with up to 90° of flex ([Figure 7](#fig7){ref-type="fig"}). The combination of these bent and flexible MASP solution structures with our earlier model for an extended planar and flexible MBL structure ([@bib20]) clarifies how the MASP and MBL structures interact with each other to activate the lectin pathway.

Flexibility of the MASP Domain Structures {#sec3.1}
-----------------------------------------

The domain flexibility in MASPs is complementary to that deduced previously for MBL. Evidence for MASP flexibility comes from (1) the differences between the experimental sedimentation coefficients and the predictions from the initial linear MASP structures ([Figures 4](#fig4){ref-type="fig"}B--4D and 4F--4H) and (2) the large deviations between the initial linear MASP structures and its experimental X-ray scattering curve. Flexibility between CUB2 and SCR1 had previously been proposed in the formation of a "closed" MASP structure in which the two SCR1-SCR2-SP moieties and the CUB1-EGF-CUB2 moiety were hypothesized to form the three sides of a triangular domain arrangement that enabled the auto-activation of the SP domains ([@bib8], [@bib35]). Flexibility between the EGF and CUB2 domains was also hypothesized to be part of an activation mechanism for the MASP-MBL complex based on a CUB2-collagen crystal structure ([@bib10]). Differences of up to 90° between the linear crystal structures and the bent solution structures described here indicate that the EGF-CUB2 junction must be particularly flexible ([Figure 7](#fig7){ref-type="fig"}). A previous structural model for full-length MASP-1 based on a crystal structure for the four domains of MAP-1 ([@bib30]) is now seen to be too elongated and rigid when this is compared to the views in [Figure 7](#fig7){ref-type="fig"}. MASP flexibility was not considered in detail in a recent SAXS analysis in which 2-fold C2 symmetry was assumed in extended MASP dimer models that were fitted to the data ([@bib19]). The current study has now provided clear evidence of MASP flexibility. The importance of bending relates to MASP auto-activation. The extent of bending observed in our best-fit MASP models may permit the two SP domains to come into contact with each other. Although this mechanism is not clearly proven by our present analyses, it cannot be excluded, as was suggested by another recent analysis ([@bib19]).

In our previous SAXS structural modeling of MBL, flexibility was deduced from a bend observed between the CRD/neck region and the linear collagen region ([@bib20]). This implies that the 9--12 CRD domains found in MBL trimers and tetramers are able to adjust their orientations and dock to a mannose-coated surface, irrespectively of the roughness of this surface. Each single CRD-mannose interaction has a low affinity, with a *K*~*D*~ of about 1 mM; multiple CRD binding increases the affinity by several orders of magnitude.

Complexes between MASP and MBL {#sec3.2}
------------------------------

Recent crystal structures for the CUB1 and CUB2 domains of C1s and MASP-2 bound to the collagen triple helices of C1q and MBL, respectively, clarify how the MASP-MBL complexes are formed ([@bib10], [@bib38]). The superimposition of these two CUB-collagen structures with our MASP-1 and MASP-2 3D crystal structures ([Figures 2](#fig2){ref-type="fig"}A and 2B) provides a complete picture of the MASP-MBL complex ([Figure 8](#fig8){ref-type="fig"}). The 61-Hyp-Gly-Lys-Leu-Gly-Pro-66 motif within the collagen triple helix of rat MBL forms the binding site for MASP-2 ([@bib42]). Common to both the CUB1-collagen and CUB2-collagen interactions is Lys46 in the collagen helices, which interacts with three of the residues that coordinate the Ca^2+^ in each CUB domain. The firm identification in this study of the three Ca^2+^ sites in rat MASP-2 now resolves a key ambiguity of the earlier rat MASP-2 structure ([@bib8]).

The combination of the MBL and MASP solution structures clarify how the MBL-MASP complex is formed:(1)Our atomistic solution structures for the MBL dimer, trimer, and tetramer showed near-planar oligomers ([@bib20]). These possess a central hub from which the two, three, or four monomers fan outward and were consistent with EM and atomic force microscopy images of human MBL oligomers ([@bib17]), which reported the most common angle between the MBL collagen monomers to be 47 ± 24°. This agreed well with our values of 63° for the dimer; 36° and 6° for the trimer; and 54°, 47°, and 51° for the tetramer ([@bib20]). Because the angle between the collagen helices in our putative MASP-MBL complexes is about 70° ([Figure 8](#fig8){ref-type="fig"}), this angular similarity shows that MBL has a pre-formed collagen conformation that is able to interact with MASP via two of the four potential binding sites. Significant conformational changes of magnitude 10°--20°, however, would be required for simultaneous binding to three or four collagenous stems by the MBL trimers and tetramers.(2)Our flexible MASP structures revise our current understanding of the activation mechanism. Intra- or inter-molecular MASP mechanisms have been proposed and both have been inferred recently ([@bib5], [@bib6]); however, there is no direct evidence for either mechanism because the changes that occur when complexes bind to a pathogen surface are not known. In the former, one-half of dimeric rat MASP-2 binds to at least two sites in a near-planar rat MBL structure, and MBL collagen flexibility is reduced when the CRD domains bind to a mannose-coated surface. This may stabilize the MASP-MBL interaction to trigger intra-molecular auto-activation between the two SP domains if they move closer together ([@bib39]). In the latter, if the MBL collagen regions form a "bunch-of-tulips" structure similar to that of the hexameric complement C1q structure, as often assumed ([@bib6]), a MASP dimer could bind to all four stems within an MBL collagen cone. The SP domains in MASP will extend outward from such an MBL cone. This binding arrangement is supported by recent EM data of complexes between human MBL tetramers and MASP-1 dimers ([@bib19]). That study also favored the inter-complex activation mechanism because it was suggested that MASP-1 polypeptides are not flexible enough to auto-activate based on SAXS and EM data. The findings described here, using SAXS combined with AUC and atomistic modeling, however, contradict this observation and show that both MASPs are much more flexible than previously thought. The observed flexibility suggests that the SP domains could bend toward each other within the complex to lead to intra-molecular MASP auto-activation upon binding to a mannose-coated surface. The choice between an intra- or inter-activation mechanism or a combination of both is presently unclear, in particular because it is not known what happens when MBL-MASP complexes bind to a pathogen surface. Certainly MASP flexibility highlighted by this present study, together with MBL flexibility, means that an intra-molecular MASP auto-activation model cannot be excluded.(3)Activation does not lead to large structural changes in the MASPs. Comparison of the zymogen and activated forms of MASP-1 and MASP-2 reveals little difference in the conformation or flexibility of MASP-1 or MASP-2. Instead, changes are presumably limited to the protease domain itself, as has been analyzed ([@bib7], [@bib9]).

Dimer Interface of the MASP Structures {#sec3.3}
--------------------------------------

A crucial issue for MASP function is the stability of the MASP dimer in physiological buffers. Although discussed for MASP crystal structures ([@bib8], [@bib12]), the observation of a crystallographic dimer does not prove that this dimer exists in solution. In this context, our AUC data showed the complete absence in solution of any monomer peaks at concentrations of 0.8--2.2 μM for full-length MASPs ([Figure 4](#fig4){ref-type="fig"}). These data indicate that the dimer dissociation constant *K*~*D*~ will be at least 100-fold less at around 10 nM or less. This is consistent with MASP dimer formation at physiological concentrations of 65--70 nM (MASP-1) and 3--5 nM (MASP-2) in human plasma ([@bib19], [@bib21], [@bib36]). Thus, the MASP dimers are stable in plasma. Stable dimers are characterized by a buried surface area in excess of 800 Å^2^ per molecule ([@bib28]). The large buried surface areas of the dimeric 3D crystal structures ([Figures 2](#fig2){ref-type="fig"}A and 2B) totaling 880--1,200 Å^2^ per molecule fully account for the existence of stable dimers in plasma.

Experimental Procedures {#sec4}
=======================

Production, Purification, and Crystallization of MASPs {#sec4.1}
------------------------------------------------------

All six rat MASPs and MASP fragments were produced and purified as described ([@bib3], [@bib41]). Rat MASP-1 and MASP-2 and their 3D fragments were produced in Chinese hamster ovary cells ([Supplemental Information](#app2){ref-type="sec"}). The zymogens were enzymatically activated. All six proteins were purified by gel filtration chromatography on a Superdex 200 16/60 column (GE Healthcare) prior to crystallization or further analysis. SDS-PAGE was used to check the purity of all of the samples. The MASP 3D fragments were crystallized by the sitting drop method using the buffers specified in the [Supplemental Information](#app2){ref-type="sec"}. X-ray diffraction data on four sets of crystals for MASP-1 and MASP-2 3D were collected at Leicester on a rotating copper anode source and at Diamond Light Source. Structures were determined by molecular replacement using the crystal structures of human MASP-1 (PDB: [3DEM](pdb:3DEM){#intref0030}) and rat MASP-2 (PDB: [1NT0](pdb:1NT0){#intref0035}) as search models. Details are provided in the [Supplemental Information](#app2){ref-type="sec"}.

X-Ray Scattering and Analytical Ultracentrifugation {#sec4.2}
---------------------------------------------------

X-ray scattering curves *I*(*Q*) for MASP were acquired in two sessions on the BioSAXS robot at Instrument BM29 at the European Synchrotron Radiation Facility, Grenoble, France ([Supplemental Information](#app2){ref-type="sec"}; [@bib25], [@bib27]). The MASPs showed no radiation damage or X-ray induced aggregation in the time frame analyses. The time-averaged runs were thus used for data analyses to determine the radius of gyration *R*~g~ and *R*~*xs*~ values from Guinier plots and the distance distribution function *P*(*r*) curves. In AUC experiments, sedimentation velocity data were obtained on Beckman XL-I instruments equipped with AnTi50 rotors and using two-sector cells with column heights of 12 mm at a rotor speed of 50,000 rpm. The sedimentation coefficient distribution *c*(*s*) analyses fitted the absorbance scans directly to the Lamm equation, in which the sedimentation coefficient was determined from the peak position.

Determination of Solution Structures of MASP-1 and MASP-2 {#sec4.3}
---------------------------------------------------------

Starting models for all the MASP solution structures were generated from crystal structures. Based on earlier experience of atomistic modeling for dimers, 2-fold symmetry was not assumed for the MASP dimer modeling, and the models sampled both symmetric and asymmetric structures. Each structural model was subjected to two sets of conformational randomization at specified inter-domain linkers to generate broad ranges of trial structures for assessment. Likely flexible linkers between the six individual MASP domains and the His-tag in the starting structures are identified in bold ([Figure 1](#fig1){ref-type="fig"})---two in the 3D proteins and five in the full-length MASPs. A dihedral angle Monte Carlo procedure was used to generate up to 30,000 domain conformations of the six MASPs using SASSIE ([@bib24]). Sterically overlapping poor models were discarded at their creation. Following this, the scattering curve simulations were performed with SCT ([@bib45]). The output was compared with the experimental X-ray scattering curves by using the calculated Guinier *R*~*g*~ and *R*~*xs*~ values and a goodness-of-fit *R* factor in order to identify the best-fit solution structures ([Supplemental Information](#app2){ref-type="sec"}). As a further validation of the scattering modeling, sedimentation coefficients *s*^*0*^~*20,w*~ for each glycosylated best-fit model were calculated directly from the atomic coordinates using WinHydroPro v1.00, setting the radius of atomic elements as 0.284 nm in order to represent the hydrated structure ([@bib22]). Full details are described in the [Supplemental Information](#app2){ref-type="sec"}.
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![Domain Organization of MASP and Its MASP-MBL Complex\
Each MASP monomer is composed of six domains. An MBL monomer is a homotrimer of three polypeptides, each forming an N-terminal cysteine-rich region, a collagen-like region, an α-helical neck region, and a C-terminal carbohydrate recognition domain (CRD). An interruption ("kink") may induce flexibility in the collagen region. A schematic MBL tetramer is shown bound to an MASP dimer at two CUB1 domains. The MASP sequences are colored according to the MASP domains. Glycosylation sites are shown in black, together with expression tags and linkers.](gr1){#fig1}

![Crystal Structures of MASP-1 and MASP-2 3D Dimers and Their Ca^2+^-Binding Sites\
(A) MASP-1 3D is shown in face-on and side-on views, related by a 90° rotation. Ca^2+^ are shown as yellow spheres.\
(B) The three structures for MASP-2 3D are in blue, green, and cyan, also shown in face-on and side-on views.\
(C) The rat MASP-1 3D structure (red) is superimposed upon its human equivalent (gray; PDB: [3DEM](pdb:3DEM){#intref0045}). All three Ca^2+^ are visible in both structures, with the Ca^2+^-binding residues shown in red.\
(D) The rat MASP-2 3D structure (blue) is superimposed upon its rat equivalent from 2003 (gray; PDB: [1NT0](pdb:1NT0){#intref0050}). All three Ca^2+^ are now visible in the new structure, again with Ca^2+^-binding residues shown in red.](gr2){#fig2}

![SAXS Guinier and *P*(*r*) Analyses\
The upper three rows correspond to MASP-1 with Ca^2+^. The bottom three rows correspond to MASP-2 with (gray) and without Ca^2+^ (black). The *R*~*g*~, *R*~*xs*~, and *P*(*r*) analyses for each protein are shown.\
(A and B) Open circles correspond to data points, and filled circles correspond to those used for the Guinier *R*~*g*~ and *R*~*xs*~ values. The *Q* ranges for the *R*~*g*~ and *R*~*xs*~ fits are arrowed ([Supplemental Information](#app2){ref-type="sec"}).\
(C) The *P*(*r*) curves were normalized to 100 for clarity. The maximum length of each molecule is denoted by *L* at the *r* values where the *P*(*r*) curves reach 0. The peak maxima *M* for the MASP 3D and *M1* and *M2* for MASP-1 and MASP-2 represent the most frequent distances within their structures.](gr3){#fig3}

![Sedimentation Velocity Analyses of the MASPs\
(A and E) Boundary fits for the zymogen of MASP-1 (0.28 mg/mL) and MASP-2 (0.14 mg/mL). Each of the 60 absorbance scans were fitted. The absorbance data are in black, whereas the boundary fits are in red.\
(B--H) The six *c*(*s*) distribution analyses are shown for each protein, from which the peaks give the *s*~*20,w*~ values. The *s*~*20,w*~ values calculated from the crystal and initial homology structures using HYDROPRO are shown as dashed lines.](gr4){#fig4}

![Atomistic Modeling Analyses of the MASPs\
(A--F) The *R* factors of the trial models versus their *R*~*g*~ values are shown for each MASP. The ten best-fit models with the lowest *R* factors are in red. For full-length MASP, the best-fit models from Search 2 are in orange. The crystal structure is shown in blue. The experimental *R*~*g*~ values are shown by vertical solid lines (arrowed) with errors of ±5% shown by dashed lines. (A) MASP-1 3D, (B) zymogen MASP-1, (C) activated MASP-1, (D) MASP-2 3D, (E) zymogen MASP-2, (F) activated MASP-2. (A, D) The 4,517 and 1,982 *R* factors are compared with the calculated *R*~*g*~ values for the MASP 3D models. (B, C, E, and F) The 6,173--30,910 *R* factors are compared with the calculated *R*~*g*~ values for the four MASP models.](gr5){#fig5}

![X-Ray Scattering Curve Fits for the Best-Fit MASP Dimer Models\
MASP-1 3D (A), zymogen MASP-1 (B), activated MASP-1 (C), MASP-2 3D (D), zymogen MASP-2 (E), activated MASP-2 (F). The experimental curves *I*(*Q*) are shown as black circles. The modeled curves *I*(*Q*) are the colored solid lines with their corresponding *R* factors in the same color. The insets show the experimental (black) and modeled (color) *P*(*r*) curves. (A, D) For MASP-1 3D and MASP-2 3D, the modeled curves for the non-glycosylated starting structures are in blue, the glycosylated starting structures are in gray, and the best-fit structures are in red. The dimer crystal structures for MASP-1 3D and MASP-2 3D are in blue, and the best-fit glycosylated structures are in red. (B, C, E, and F) The modeled curves for the non-glycosylated starting structures are in blue. The curves from the best-fit MASP models from Search 1 are red whereas those from Search 2 are orange. The starting homology dimer models for zymogen or activated MASP-1 or MASP-2 are in blue, and those in red are one of the best-fit MASP dimer models from Search 1. The starting and best-fit structures are superimposed at the CUB1-EGF domains.](gr6){#fig6}

![The Best-Fit Solution Structures of the MASP Dimers\
MASP-1 3D (A), zymogen MASP-1 (B), activated MASP-1 (C), MASP-2 3D (D), zymogen MASP-2 (E), activated MASP-2 (F). For each protein, the ten best-fit models were aligned based on their steric similarities to show their bent shapes. The views to the right show views that were rotated by 90° about their longest axes.](gr7){#fig7}

![Summary View of the MBL-MASP Complex from Crystallography and Scattering Analyses\
Face-on (A) and side-on (B) views of the MBL-MASP complex rotated by 90°. The complex is represented as secondary structure ribbons for four collagen helices bound to MASP-3D at the center. The collagen triple helices bind to the Ca^2+^ sites of the CUB1 and CUB2 domains ([Figures 2](#fig2){ref-type="fig"}C and 2D). The flexible regions between the CUB2 and EGF domains are arrowed in black. The MBL-MASP complex was assembled from (1) the complex of the MASP-1 CUB2 domain with collagen (yellow; PDB: [3POB](pdb:3POB){#intref0055}), (2) the C1s 3D complex with a collagen-like peptide from C1q to represent the CUB1 complex (pink; PDB: [4LOR](pdb:4LOR){#intref0060}), and (3) one of the three MASP-2 3D crystal structures from this study (cyan; PDB: [5CKN](pdb:5CKN){#intref0065}; [Table 1](#tbl1){ref-type="table"}).](gr8){#fig8}

###### 

Crystallographic Data Collection and Refinement Statistics for Rat MASP-2 3D and MASP-1 3D

                            MASP-2 MPD/Acetate              MASP-2 PEG 20K                  MASP-2 MPD/Citrate              MASP-1
  ------------------------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  **Data Collection**                                                                                                       
                                                                                                                            
  Beamline                  Diamond I04-1                   Diamond I04-1                   Cu^2+^ home source              Diamond I04
  Space group               P 2~1~ 2~1~ 2~1~                C 2 2 2~1~                      C 2 2 2~1~                      I 2 3
  a, b, c (Å)               83.6, 91.3, 127.1               66.9, 98.3, 121.4               82.9, 119.4, 104.0              152.7, 152.7, 152.7
  α, β, γ, °                90, 90, 90                      90, 90, 90                      90, 90, 90                      90, 90, 90
  Resolution (Å)            63.6--2.6 (2.69--2.60)          50.3--2.58 (2.60--2.58)         22.9--2.73 (2.82--2.73)         76.4--3.70 (4.14--3.70)
  *R*~*sym*~                0.082 (0.321)                   0.099 (0.645)                   0.167 (0.653)                   0.082 (0.743)
  *I/σ*(*I*)                16.04 (2.10)                    11.55 (2.03)                    6.4 (1.53)                      9.2 (1.51)
  Completeness              97.6 (98.8)                     97.6 (93.5)                     99.4 (94.4)                     99.9 (99.9)
  Redundancy                5.0 (5.2)                       3.9 (3.6)                       2.0 (2.0)                       5.6 (5.5)
                                                                                                                            
  **Refinement**                                                                                                            
                                                                                                                            
  Resolution (Å)            63.55--2.6 (2.69--2.60)         50.34--2.58 (2.67--2.58)        22.9--2.73 (2.82--2.73)         76.4--3.70 (3.84--3.70)
  No. of reflections        29,893 (2,998)                  12,626 (1,195)                  14,031 (1,319)                  6,473 (1827)
  *R*~*work*~*/R*~*free*~   0.205/0.254                     0.207/0.245                     0.204/0.266                     0.248/0.294
  No. of atoms              4,502                           2,303                           2,369                           2,271
  Protein                   4,433                           2,208                           2,211                           2,239
  Ligand/ion                6                               17                              17                              32
  Water                     63                              78                              141                             --
  B factors (Å^2^)          93.40                           51.60                           34.70                           187.20
  Protein                   93.90                           51.70                           35.00                           187.60
  Ligand/ion                65.80                           78.20                           65.90                           155.50
  Water                     62.30                           44.30                           26.80                           --
  PDB                       [5CKN](pdb:5CKN){#intref0070}   [5CIS](pdb:5CIS){#intref0075}   [5CKM](pdb:5CKM){#intref0080}   [5CKQ](pdb:5CKQ){#intref0085}
  RMSDs                                                                                                                     
  Bond lengths (Å)          0.004                           0.003                           0.004                           0.002
  Bond angles (°)           1.01                            0.72                            0.82                            0.75
  Ramachandran (%)                                                                                                          
  Favored                   94                              93                              94                              92
  Allowed                   6                               7                               6                               8
  Disallowed                0                               0                               0                               0

The buffers are defined in full in the Supplemental Information. The highest resolution shell is shown in parentheses.

###### 

Experimental and Modeled X-Ray Scattering and Sedimentation Coefficient Data

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
                                *R*~*g*~ (nm)[a](#tblfn1){ref-type="table-fn"}   *R*~*xs*~ (nm)   *L* (nm)     *s*~*20,w*~ (S)[b](#tblfn2){ref-type="table-fn"}
  ----------------------------- ------------------------------------------------ ---------------- ------------ --------------------------------------------------
  **Experimental**                                                                                             

                                                                                                               

  MASP-1 3D (12 curves)         3.79 ± 0.01\                                     1.94 ± 0.01      13           4.53 ± 0.08
                                3.97 ± 0.01                                                                    

  MASP-2 3D (9 curves)          3.87 ± 0.02\                                     1.74 ± 0.02      12           4.09 ± 0.07
                                3.99 ± 0.01                                                                    

  Zymogen MASP-1 (14 curves)    7.93 ± 0.09\                                     1.54 ± 0.02      26           5.90 ± 0.15
                                8.23 ± 0.02                                                                    

  Activated MASP-1 (8 curves)   7.86 ± 0.12\                                     1.53 ± 0.02      26           5.79 ± 0.13
                                8.22 ± 0.02                                                                    

  Zymogen MASP-2 (9 curves)     7.58 ± 0.13\                                     1.46 ± 0.06      27           5.42 ± 0.15
                                7.98 ± 0.02                                                                    

  Activated MASP-2 (4 curves)   7.54 ± 0.04\                                     1.46 ± 0.05      26           5.62 ± 0.16
                                7.79 ± 0.04                                                                    

                                                                                                               

  **Best-Fit Models**                                                                                          

                                                                                                               

  MASP-1 3D                     3.79 ± 0.09                                      1.93 ± 0.03      14.1 ± 0.7   4.25 ± 0.07

  MASP-2 3D                     3.92 ± 0.07                                      1.89 ± 0.33      14.3 ± 0.5   3.96 ± 0.03

  Zymogen MASP-1                7.73 ± 0.17                                      1.71 ± 0.06      26.4 ± 0.9   5.92 ± 0.05

  Activated MASP-1              8.09 ± 0.23                                      1.67 ± 0.10      25.1 ± 1.2   5.92 ± 0.07

  Zymogen MASP-2                7.34 ± 0.27                                      1.32 ± 0.22      23.5 ± 1.0   5.69 ± 0.10

  Activated MASP-2              7.70 ± 0.18                                      1.49 ± 0.10      25.3 ± 1.1   5.61 ± 0.10
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

The mean *R*~*g*~ values from the Guinier analyses are shown first, followed by the mean *R*~*g*~ values from the *P*(*r*) analyses, the mean *R*~*xs*~ values from the Guinier analyses, and the mean *L* values from the *P*(*r*) analyses ([Figure 3](#fig3){ref-type="fig"}).

The mean *s*~*20,w*~ values observed at 50,000 rpm are shown ([Figure 4](#fig4){ref-type="fig"}).

[^1]: Lead Contact
